These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
92 related articles for article (PubMed ID: 18073335)
1. Mechanism for ubiquitylation of the leukemia fusion proteins AML1-ETO and PML-RARalpha. Krämer OH; Müller S; Buchwald M; Reichardt S; Heinzel T FASEB J; 2008 May; 22(5):1369-79. PubMed ID: 18073335 [TBL] [Abstract][Full Text] [Related]
2. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells. Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244 [TBL] [Abstract][Full Text] [Related]
3. Differential regulation of PML-RARα stability by the ubiquitin ligases SIAH1/SIAH2 and TRIAD1. Pietschmann K; Buchwald M; Müller S; Knauer SK; Kögl M; Heinzel T; Krämer OH Int J Biochem Cell Biol; 2012 Jan; 44(1):132-8. PubMed ID: 22037423 [TBL] [Abstract][Full Text] [Related]
4. Honokiol induces proteasomal degradation of AML1-ETO oncoprotein via increasing ubiquitin conjugase UbcH8 expression in leukemia. Zhou B; Li H; Xing C; Ye H; Feng J; Wu J; Lu Z; Fang J; Gao S Biochem Pharmacol; 2017 Mar; 128():12-25. PubMed ID: 28043811 [TBL] [Abstract][Full Text] [Related]
5. PML-RARalpha and AML1-ETO translocations are rarely associated with methylation of the RARbeta2 promoter. Tabe Y; Konopleva M; Kondo Y; Contractor R; Jin L; Ruvolo V; Tsutsumi-Ishii Y; Miyake K; Miyake N; Ohsaka A; Nagaoka I; Issa JP; Andreeff M Ann Hematol; 2006 Oct; 85(10):689-704. PubMed ID: 16832676 [TBL] [Abstract][Full Text] [Related]
14. Autophagy: friend or foe in the treatment of fusion protein-associated leukemias? Torgersen ML; Simonsen A Autophagy; 2013 Dec; 9(12):2175-7. PubMed ID: 24145192 [TBL] [Abstract][Full Text] [Related]
15. Novel role of HDAC inhibitors in AML1/ETO AML cells: activation of apoptosis and phagocytosis through induction of annexin A1. Tabe Y; Jin L; Contractor R; Gold D; Ruvolo P; Radke S; Xu Y; Tsutusmi-Ishii Y; Miyake K; Miyake N; Kondo S; Ohsaka A; Nagaoka I; Andreeff M; Konopleva M Cell Death Differ; 2007 Aug; 14(8):1443-56. PubMed ID: 17464329 [TBL] [Abstract][Full Text] [Related]
16. [Dexamethasone and vorinostat cooperatively promote differentiation and apoptosis in Kasumi-1 leukemia cells through ubiquitination and degradation of AML1-ETO]. Chen LP; Zhang JW; Xu FM; Xing HY; Tian Z; Wang M; Wang JX Zhonghua Xue Ye Xue Za Zhi; 2013 Sep; 34(9):741-4. PubMed ID: 24103869 [TBL] [Abstract][Full Text] [Related]
17. Epigenetic silencing of Bcl-2, CEBPA and p14(ARF) by the AML1-ETO oncoprotein contributing to growth arrest and differentiation block in the U937 cell line. Zhuang WY; Cen JN; Zhao Y; Chen ZX Oncol Rep; 2013 Jul; 30(1):185-92. PubMed ID: 23673926 [TBL] [Abstract][Full Text] [Related]
18. Leukemogenic AML1-ETO fusion protein upregulates expression of connexin 43: the role in AML 1-ETO-induced growth arrest in leukemic cells. Li X; Xu YB; Wang Q; Lu Y; Zheng Y; Wang YC; Lübbert M; Zhao KW; Chen GQ J Cell Physiol; 2006 Sep; 208(3):594-601. PubMed ID: 16741927 [TBL] [Abstract][Full Text] [Related]
19. Cell type dependent regulation of multidrug resistance-1 gene expression by AML1-ETO. Hines R; Boyapati A; Zhang DE Blood Cells Mol Dis; 2007; 39(3):297-306. PubMed ID: 17590361 [TBL] [Abstract][Full Text] [Related]
20. AML1-ETO targets and suppresses cathepsin G, a serine protease, which is able to degrade AML1-ETO in t(8;21) acute myeloid leukemia. Jin W; Wu K; Li YZ; Yang WT; Zou B; Zhang F; Zhang J; Wang KK Oncogene; 2013 Apr; 32(15):1978-87. PubMed ID: 22641217 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]